Fake retatrutide, real danger: unapproved peptide caused oesophageal tear

A vial labelled retatrutide.

The patient who bought it was trying to lose weight. The product arrived looking like any other injectable peptide — a small vial, a label, a plausible name. What happened next was nearly fatal: extreme nausea, forceful vomiting, and a torn oesophagus. Gastroenterologist Darcy Holt, who treated the patient, described the prognosis of an untreated oesophageal rupture as “almost universally fatal.”

This is not a story about a bad batch. It is a story about a market where the label means nothing.

---

What was actually in the vial

The TGA arranged laboratory testing. The product contained no retatrutide. What it actually contained was undeclared semaglutide — at approximately eight times the standard dose found in TGA-assessed products like Ozempic and Wegovy.

Retatrutide is a triple-receptor agonist — acting on GIP, GLP-1, and glucagon receptors — that is currently in phase 3 clinical trials. It is not approved by the TGA. It is not approved by the FDA, the EMA, or any comparable regulator. Nobody outside a controlled trial setting knows what the appropriate human dose is, because that question has not yet been answered. Products labelled as retatrutide purchased online are not what they claim to be, and there is no legitimate supply chain to buy from.

The TGA’s statement is worth holding onto: “the biggest risks with unapproved peptide products are not knowing what is in the vial, how much of, or even what substance it contains.” That is not a bureaucratic hedge. It is exactly what happened here.

---

Both sides of this

The honest complexity is that the patients using these products are not reckless. Many are people for whom legitimate access to weight-management medicine has been difficult — facing cost barriers to PBS-listed GLP-1 agonists, long waits with specialist clinics, or GPs reluctant to prescribe outside established criteria. The black market fills gaps that the healthcare system creates. That doesn’t make it safe. It makes it more understandable.

And it does mean that a question worth asking — not of the patient, but of the system — is why people are turning to unregulated injectables they source from websites. The pharmacovigilance conversation and the access conversation need to happen at the same time.

That said, the clinical reality does not move. Semaglutide at eight times the therapeutic dose — whether from a mislabelled vial or any other source — causes extreme nausea and forceful vomiting. Forceful vomiting can tear the oesophagus — a Boerhaave-pattern injury that is a surgical emergency. Gastroenterologist Holt also documented other peptide-related presentations over the past three to six months: liver toxicity, severe secretory diarrhoea. The pattern is not isolated.

---

What this means this week

If someone you know — or you yourself — is using injected peptides sourced outside the formal healthcare system, the message is simple: the label does not guarantee the contents, and the dose is unknown. That is not a theoretical risk. It is what the laboratory found.

For GPs, the conversation shift worth noting is that peptide use is now showing up in presentations that are not obviously connected to weight management. Unexplained nausea, vomiting, diarrhoea, or elevated liver enzymes in a patient who is trying to manage weight: it is worth asking the direct question in a non-judgmental way.

And if severe vomiting or chest/abdominal pain develops in anyone injecting peptides of unknown provenance — this is an emergency presentation.

---

Verdict: yes — worth knowing about.

Not because the risk is new, but because it has just become visible in a very specific, very concrete way. The label means nothing. The dose is unknown. This is the market operating exactly as it does.

---

Sources cited

1. Fresh warning after peptide user suffers torn oesophagus — ABC Health (14 Sep 2026)
2. TGA — using unapproved products
3. Boerhaave syndrome — StatPearls / NCBI Bookshelf